Equities research analysts expect Senseonics Holdings, Inc. (NASDAQ:SENS) to post sales of $4.05 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Senseonics’ earnings, with the highest sales estimate coming in at $4.05 million and the lowest estimate coming in at $4.04 million. Senseonics posted sales of $2.95 million in the same quarter last year, which would indicate a positive year over year growth rate of 37.3%. The company is scheduled to announce its next earnings results on Thursday, May 9th.

On average, analysts expect that Senseonics will report full-year sales of $27.79 million for the current year, with estimates ranging from $27.47 million to $28.10 million. For the next financial year, analysts expect that the firm will report sales of $68.12 million, with estimates ranging from $55.92 million to $80.31 million. Zacks’ sales averages are an average based on a survey of analysts that cover Senseonics.

Senseonics (NASDAQ:SENS) last issued its earnings results on Tuesday, March 12th. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.11. The firm had revenue of $7.20 million during the quarter, compared to the consensus estimate of $7.89 million.

Shares of Senseonics stock remained flat at $$2.08 on Wednesday. 908,731 shares of the stock traded hands, compared to its average volume of 1,795,580. Senseonics has a 12 month low of $2.00 and a 12 month high of $5.29.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Featured Story: The components of the Stochastic Momentum Index

Get a free copy of the Zacks research report on Senseonics (SENS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.